Xencor, Inc. XNCR
Updated: 18 Jun 2026
No signal published yet
We already track Xencor and collect the news. No signal is published yet — follow the company free and we will email you when that changes, or run a quick check now.
Email when we publish a signal or something material happens · Sunday weekly brief
No card · No time limit on free tier · Upgrade when you need more
Temporary check — not Firelda's published signal.
General analysis — not personal advice.
Want to follow Xencor, Inc.? Create a free account — 3 companies, change history, weekly brief, and email when the picture changes.
Follow Xencor free Follow freeEmail when we publish a signal or something material happens · Sunday weekly brief
No card · No time limit on free tier · Upgrade when you need more
Recent News
On May 6, 2026, Xencor reported first-quarter results with a cash position of $541.8 million and presented Phase 1 data for XmAb942 supporting a quarterly dosing schedule. The company also announced a new clinical study evaluating the combination of XmAb541 and XmAb808 for ovarian cancer. Clinical data from a Phase 1 expansion cohort in renal cell carcinoma is expected in the second half of 2026.
What Firelda Watch includes for Xencor, Inc.
Add the company to your watchlist and get all of this automatically.
- Free: 3 companies on your watchlist
- Change history and monitoring for every company you follow
- Sunday weekly brief — a short weekly roundup
- Watch/Ultra: same-day email when something material happens
Want to see what a finished analysis looks like?
View a sample analysis
Want to follow Xencor, Inc.? Create a free account — 3 companies, change history, weekly brief, and email when the picture changes.
Follow Xencor free Follow freeEmail when we publish a signal or something material happens · Sunday weekly brief
No card · No time limit on free tier · Upgrade when you need more